perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### Article

# Tracking the Progression & Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study using PET Images

Gautam Kumar Baboo <sup>1</sup>, Raghav Prasad <sup>1</sup>, Pranav Mahajan <sup>1</sup> and Veeky Baths <sup>1,\*</sup>

1

21

23

C-115, Cognitive Neuroscience Lab, Department of Biological Sciences, BITS-Pilani - K.K. Birla Goa Campus:

Abstract: (1) Background: Network analysis allows investigators to explore the many facets

- F. author p20130404@goa.bits-pilani.ac.in
- S.author: f20170297@goa.bits-pilani.ac.in,
- T. author: f20170277@goa.bits-pilani.ac.in
- Correspondence: veeky@goa.bits-pilani.ac.in

of brain networks, particularly the proliferation of disease. One of the hypotheses behind the disruption in brain networks in Alzheimer's disease is the abnormal accumulation of beta-amyloid 3 plaques and tau protein tangles. In this study, the potential use of percolation centrality to study beta-amyloid movement was studied as a feature of given PET image-based networks; (2) Methods: The PET image-based network construction is possible using a public access database - Alzheimer's Disease Neuroimaging Initiative, which provided 551 scans. For each image, the Julich atlas provides 121 regions of interest, which are the network nodes. Besides, using the collective influence algorithm, the influential nodes for each scan are calculated; (3) Analysis of variance (p<0.05) yields the region of interest Gray Matter Broca's Area for PiB tracer type for five 10 nodal metrics. In comparison, AV45: the Gray Matter Hippocampus region is significant for three 11 of the nodal metrics. Pairwise variance analysis between the clinical groups yields five and twelve 12 statistically significant ROIs for AV45 and PiB, capable of distinguishing between pairs of clinical 13 conditions. Multivariate linear regression between the percolation centrality values for nodes and 14 psychometric assessment scores reveals Mini-Mental State Examination is reliable(4) Conclusion: 15 percolation centrality effectively (41% of ROIs) indicates that the regions of interest that are part 16 of the memory, visual-spatial skills, and language are crucial to the percolation of beta-amyloids 17 within the brain network to the other widely used nodal metrics. Ranking the regions of interest based on the collective influence algorithm indicates the anatomical areas strongly influencing the 19 beta-amyloid network. 20

Keywords: Brain Mapping; P.E.T.; Neurodegenerative Disorders; Alzheimer's Disease; Graph Theory; Percolation Centrality; Collective Influence. 22

# 1. Introduction

Alzheimer's disease predominantly stands out when it comes to neurodegenerative 24 diseases affecting the middle-age (early-onset Alzheimer's disease (A.D.)) and the old-25 26 age (Late-onset AD) human population. Current projections are estimated to cost about 2 trillion U.S. Dollars by 2030[1] affecting 75 million individuals by the same year. The 27 indirect costs are estimated to be about 244 billion U.S. Dollars[2]. With no sight of a 28 cure for A.D. and with increasing cases, early diagnosis and active management are the 29 keys to tackling this disease for now. The ability to predict the disease's progression 30 with high accuracy helps design a suitable treatment regime at an early stage, thereby 31 bringing the disease's management to an affordable cost range. 32

invasive techniques of investigations ranging from Positron Emission Tomography (PET)

Citation: Kumar B., Gautam.: Prasad, Raghav.; Mahajan, Pranav.; Baths, Veeky. Percolation Centrality and Collective Influence on Beta-amyloid plaques network. Journal Not Specified 2021, 1, 0. https://doi.org/

Received: Accepted: Published:

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Submitted to Journal Not Specified for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons of the the preprint reports new researched the new researched to the new 4.0/).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license

Version July 19, 2021 submitted to Journal Not Specified

2 of 22

scans[3] or Cerebrospinal Fluid (CSF) analysis[4]. Positron Emission Tomography or PET
imaging involves the use of radiopharmaceuticals such as 2-[18F], florbetapir-fluorine-18
(AV45), or 11C-Pittsburgh compound B (PiB). AV45 and PiB[5] are comparatively newer
and different in terms of the image construction mechanism. Both AV45 and PiB bind to
beta-amyloid but vary in their half-life. AV45 has a half-life of 109.75 minutes and PiB,
20 minutes[6]. A comparison between PiB and AV45 varies because AV45 shows uptake

<sup>41</sup> within the white matter regions[7].

A combination of techniques or criteria is currently employed to detect and determine the extent of dementia due to AD. Methods which include family history, psychiatric history for cognitive and behavioral changes, which is then followed by psychometric assessments such as Mini-Mental State Examination (MMSE)[8], Frontal Assessment Battery[9] and the Neuropsychiatric Inventory Questionnaire (NPIQ)[10].

The MMSE questionnaire provides assessment in five areas of cognitive function;
Orientation, Attention, Memory, Language, and Visual-Spatial skills. Similarly, the NPI
questionnaire provides assessment in twelve neuropsychiatric symptoms. These two
questionnaires provide the classification of the patients into three clinical conditions;
cognitively normal, mild cognitive impairment, and dementia due to A.D.

The application of network analysis/graph theory to anatomical neural networks has proved useful in understanding the brain connectivity[11,12](deviations under various psychological and neurological disease states. Network analysis on neuroimaging data such as EEG, MEG, fMRI, and PET scans proves to be useful to show the variation between a cognitively normal population versus other diagnostic states using various graph-theoretic metrics[13,14].

Graph metrics such as characteristic path length, clustering coefficient, modularity, 58 and hubs have been studied and have provided insights into the brain networks of AD 59 patients and control groups. Some studies have tried to map the progression of MCI 60 to dementia due to AD[15,16]; thus, network analysis and the various graph metrics 61 have shown potential as a tool to investigate the brain networks. Network analysis 62 on AD is a practical application wherein it describes the Alzheimer's brain network's 63 behaviour. Connectivity analysis using fMRI and EEG data reports provides mixed responses; when comparing AD patients and the control group [17], there is an increase 65 or decrease in the network's connectivity. A reduction in connectivity could explain the cortical atrophy/disruption of the network. An increase could explain the compensatory 67 mechanism<sup>[18]</sup>.

Network Analysis on PET images related to A.D. mainly revolve around learning models or are limited to tracers that focus on the metabolic networks and the associated deviations of these networks[19,20]. Other methods include applying algorithms to the raw PET images to recognize patterns to resolve differences between healthy controls and patients with neurodegeneration[21]. The use of PET imaging and lumbar puncture to determine the levels of beta amyloids in either of them beyond the normal levels is the current standard of practice for the determination of dementia due to A.D.[22,23].

To understand beta-amyloid propagation, we propose applying graph theoretic
 methods on PET images to understand beta-amyloid advancement. The main benefit of
 adding this method is that

This does not introduce any new steps for data collection from the patient and, at
 the same time.

Adds value to the existing data by computing the percolation centrality of a given node at a given time

Network topology offers insights into the evolution of the network in a clinical
 setting. Studying such an evolution provides a possibility to understand the weak
 links within Julich atlas[24–26] based region of interest(ROI) networks. Such networks'
 structural connectivity information might yield the source and sink of neurodegeneration
 with the brain architecture.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

Percolation centrality is defined as the proportion of 'percolated paths' that pass

through that node; this measure quantifies the relative impact of nodes based on their

<sup>90</sup> topological connectivity, as well as their percolated states. In other words, it is one

<sup>91</sup> such graph metric that looks at the extent to which a given node within a network

has percolated information or can percolate information(Figure 1). The volume of

information transmitted via a given node is provided by values ranging from 0.0 to
 1.0[27,28]. Prior exploration of percolation centrality on disease networks[28–31] and

percolation centrality in disease networks of the brain[32] have shown this as a promising

<sup>96</sup> metric for brain network investigation.

The knowledge on the application of percolation centrality on human PET-image-97 based networks is scarce at present. This work aims at adding knowledge to the gap. 00 On the other hand, collective influence provides a minimum set of nodes or regions 99 of the interest that can transfer information or spread disease with ease with optimal 100 spread[33] based on the optimal percolation theory. By examining the network for the 101 minimum set of nodes, this set will provide the regions of interest within the brain that 102 optimally move beta-amyloid, disrupting the normal functioning of the existing neural 103 networks. 104

Thus, the ability to detect the disease and predict the rate of progression of the disease at an early stage is imperative. To this end, the study aims to answer two main questions:

1) Can percolation centrality measure be used to determine the percolation of beta-amyloids within the brain?

2) Can the collective influence algorithm provide a minimum set of nodes that arevital to the AD network?

# 112 2. Materials and Methods

113 2.0.1. Patient Distribution

Based on the tracer agents used for acquiring the PET images, each diagnostic state 114 subset of the data set is divided into the two available tracers; AV45[34] and PiB[6]. The 115 patients are categorized as Cognitively normal, with Mild Cognitive Impairment, or 116 having Alzheimer's Disease (AD) based on the ADNI study's psychometric assessments. 117 Next, the PET image is matched with the patient's diagnostic state at the time of the 118 imaging procedure. This provided a set of observations for each type of tracer for each 119 patient condition clinical group((Table 1). Finally, the resulting set of patients is matched 120 with the demographic information providing 531 patients. 121

- 122 2.1. Network Construction and Processing
- 123 2.1.1. PET Image preprocessing
- Image preprocessing is carried out in two steps (Figure 2):
- Combining individual frames of the PET image to form a 4D raw activity image.
   This is done using the fslmerge utility included in FSL[35].
  - 2. The 4D raw activity image is converted to a 4D SUV image using the following formula:

$$SUV = \frac{c_{img}}{c_{inj}} \tag{1}$$

where  $c_{img}$  (Mbq ml<sup>-1</sup>) is given by the raw activity image and  $c_{inj} = \frac{ID}{BW}$ . *ID* (MBq) is the injection dose[36], and *BW* (g) is the body weight of the patient, considering the equivalency 1g = 1ml

Spatially realigning the PET frames to correct for motion. This was done using
 MCFLIRT.[37] The motion correction occurs with 6 DOF. The PET frames are
 realigned using the mean image as a template. The mean image is obtained by
 applying the motion correction parameters to the time series and averaging the

volumes.

Version July 19, 2021 submitted to Journal Not Specified

- 4. Coregistering the 4D SUV image from subject space to MNI[38] space. This is done 135 using FreeSurfer[39]. The image used for coregistration is the MNI152\_T1\_2mm\_brain. 136
  - To parallelize this operation, GNU Parallel[40] is used.

#### 2.2. PET Image-based Network Construction 13

The network is constructed using the regions of interest (ROIs) from the Julich 139 Atlas. This atlas provides 121 ROIs, which translates to 121 nodes or vertices in the 140 network((Figure 3). Building networks from the preprocessed images requires the 141 generation of adjacency matrices. The adjacency matrix is computed by calculating the method described below. 143

The Bivariate Pearson correlation performs poorly in cases of "confounding" or 144 "chain" interactions. In such cases, partial correlation measures the direct connectivity 145 between two nodes by estimating their correlation after regressing out effects from all the other nodes in the network, hence avoiding spurious effects in network modeling. 147 Whereas in cases of "colliding" interactions, a partial correlation may induce a spurious 148 correlation. Thus, Sanchez-Romero and Cole have introduced a combined multiple 149 functional connectivity method[41]. 150

The network is constructed by computing the pairwise partial correlation values of 151 voxel intensities in the PET images to produce an initial adjacency matrix (matrix<sub>part</sub>). A 152 second matrix ( $matrix_{bivar}$ ) is constructed by computing the bivariate correlation values 153 of voxel intensities in the PET images. Now, matrixpart is modified using matrixbivar as 154 follows: 155

$$matrix_{part}(i,j) = \begin{cases} 0 & if \ matrix_{bivar}(i,j) = 0\\ no \ change & otherwise \end{cases}$$
(2)

where  $matrix_{part}(i, j)$  and  $matrix_{bivar}(i, j)$  is the element at (i, j) in the respective 156 matrices.  $matrix_{part}$  is now the combinedFC adjacency matrix that defines the net-157 work((Figure 4).

The partial correlation is calculated using the correlation between two residuals; 159 the values are computed using N - 2 ROIs as co-factors for every pair of ROIs[42]. The 160 partial correlation values serve as the edge weights and constitute the values in the 161 adjacency matrices. 162

Partial correlations are computed as correlation of residuals. The first order partial 163 correlation ( $\rho_{ij,k}$ ) of  $x_i$  and  $x_j$ , controlling for  $x_k$  is given by [43]. 164

$$corr(resid(i|k), resid(j|k)) = \frac{c_{ij} - c_{ik}v_kc_{kj}}{\sqrt{v_i - c_{ik}v_kc_{ki}}\sqrt{v_j - c_{jk}v_kc_{kj}}}$$
(3)

where  $c_{ij} = cov(x_i, x_j)$  and  $v_k = var(x_k)$  Further,

$$\rho_{ij,k} = \frac{\rho_{ij} - \rho_{ik}\rho_{jk}}{\sqrt{1 - \rho_{ik}^2}\sqrt{1 - \rho_{jk}^2}}$$
(4)

Since we are controlling for (N - 2) ROIs for each pair of ROIs  $ROI_i$  and  $ROI_i$ , we 165 calculate the  $(N-2)^{th}$  order partial correlation. This is calculated recursively as 166

*For each*  $ROI_k \in \mathbf{ROIs}$ 

$$\rho_{ij.\mathbf{ROIs}} = \frac{\rho_{ij.\mathbf{ROIs}\setminus\{k\}} - \rho_{ik.\mathbf{ROIs}\setminus\{k\}}\rho_{kj.\mathbf{ROIs}\setminus\{k\}}}{\sqrt{1 - \rho_{ik.\mathbf{ROIs}\setminus\{k\}}^2}} \quad (5)$$

The base case of this recursive algorithm is given by equation 3. The estimation of 167 partial correlations is a computationally intensive task, mainly due to the pre-calculation 168

Version July 19, 2021 submitted to Journal Not Specified

of residuals before computing cross-correlation. And because the number of covariates is 169 large; this calculation is done in a time-optimized manner using the R package ppcor[43]. 170

Next, the adjacency matrices with set threshold; using a) data-driven threshold scheme based on Orthogonal Minimal Spanning Trees (OMSTs)[21,44,45]. Network 172 threshold serves to remove inconsequential (or low-impact) edges and reduce the net-173 work complexity. And b) shortest path thresholding scheme [46]. This is done to compare 174 between the two common schemes used for threshold. 175

The Networkx<sup>[47]</sup> Python library is used for network construction from the thresh-176 old adjacency matrices and subsequent percolation centrality computation and other 177 graph metrics. 178

### 2.3. Percolation Centrality Computation 179

Percolation centrality is a nodal metric and is calculated for each node. The percolation centrality for each node v at time t is calculated as shown below:

$$PC^{t}(v) = \frac{1}{(N-2)} \sum_{s \neq v \neq r} \frac{\sigma_{s,r}(v)}{\sigma_{s,r}} \frac{x_s^t}{[\sum x_v^t] - x_v^t}$$
(6)

Where  $\sigma_{s,r}$  is the number of shortest paths between nodes s and r pass-through node v, 180  $x_i^t$  is the percolation state of node *i* at time *t*, 181

 $x_i^t = 0$  indicates a non-percolated node and, 182

= 1 indicates a fully percolated node.  $x^t$ 183

The percolation centrality value is calculated for each network using the inbuilt 184 function of Networkx.(see supplementary data) 185

### 2.4. Collective Influence Algorithm 186

We define G(q) the fraction of occupied sites (or nodes) belonging to the gi-187 ant(largest) connected component. Percolation theory[48] tells us that if we choose 188 these q fraction of nodes randomly, the network undergoes a structural collapse at a cer-189 tain critical fraction where the probability of existence of the giant connected component 190 vanishes, G = 0. The optimal percolation problem is finding the minimum fraction  $q_c$  of 191 nodes to be removed such that  $G(q_c) = 0$  i.e. the minimum fraction of "influencers" to 192 fragment the network. For any fixed fraction  $q < q_c$ , we search for the configuration of removed nodes that provides the minimal non-zero giant connected component G. For 194 further reading on how the problems of optimal immunization and spreading (optimal 195 influencer problem) to the problem of minimizing the giant component of a network, 196 i.e., optimal percolation problem, readers are encouraged to read [49].

The algorithm is on the basis that, given a network: the flow of information within 198 the network is optimal with a minimum number of nodes that weigh heavily on the 1 9 9 flow of information through the said network[33]. In the context of this investigation, 200 the small sets of nodes/ROIs would prove to be vital in the movement of beta-amyloid 201 plaques. 202

The core idea is that the overall functioning of a network in terms of the spread of 203 information (or in our case, movement of beta-amyloid plaques) hinges on a specific 204 set of nodes called influencers. This idea of finding the most influential nodes has been 205 previously used in other contexts, for example, activating influential nodes in social 206 networks to spread information[50] or de-activating or immunizing influential nodes to 207 prevent large scale pandemics[30,51]. In recent applications to neuroscience, this method 208 has been used to find nodes essential for global integration of a memory network in 209 rodents[32]. Our work is the first to apply it to study the progression of AD, to the best 210 of our knowledge. In the context of this investigation, these small sets of influential 211 nodes/ROIs would prove to be vital in the movement of beta-amyloid plaques. 212

With the implementation of Collective Influence (CI) algorithm, it facilitates to 213 pinpoint the most influential nodes, more efficiently than previously known heuristic 214

Version July 19, 2021 submitted to Journal Not Specified

techniques. CI is an optimization algorithm that aims to find the minimal set of nodes 215 that could fragment the network in optimal percolation, or in a sense, their removal 216 would dismantle the network in many disconnected and non-extensive components. 217 In percolation theory, if we remove nodes randomly, the network would undergo a 218 structural collapse at a critical fraction where the probability that the giant connected 219 component exists is G = 0. The optimal percolation is an optimization problem that 220 attempts to find the minimal fraction of influencers q to achieve the result G(q) = 0. 221

#### 2.5. Other Graph metrics 222

Besides the percolation centrality measure, four other nodal metrics of a graph are 223 calculated here. Below are the four metrics that are computed for the PET image based 224 graphs. 225

2.5.1. Betweenness Centrality 226

The basic definition of betweenness centrality is defined as, 227

$$C_B(u) = \frac{\sum_{s \neq u \neq t} \frac{\partial_{st}(u)}{\partial_{st}}}{(n-1)(n-2)/2} \tag{7}$$

This centrality information provides the uniqueness of it within the network. In 228 this study it provides the regions of interest that play a vital role in the information flow 220 in the network; the information being beta-amyloids or tau proteins accumulation in 230 those regions. 231

#### 2.5.2. Closeness Centrality 232

The closeness centrality of a node denotes how close a node is in the given network. 233 It is inversely proportional to the farness of the node. Freeman defined the closeness 234 centrality as, 235

$$C_c(u) = \frac{n-1}{\sum_{\forall u, v \neq u} d(u, v)}$$
(8)

The distance between two nodes/ROIs u and v in a network, denoted d(u,v), is 236 defined as the number of hops made along the shortest path between u and v. In this 237 case, lesser the hops; closer are the two ROI's and the ease with which the misformed 238 proteins can travel. 239

### 2.5.3. Current Flow Betweenness Centrality 240

Given a source ROI(s) and a target ROI(t), the absolute current flow through edge 241 (i, j) is the quantity  $A_{i,j}|v_i^{(s,t)} - v_j^{(s,t)}|$ . By Kirchhoff's law the current that enters a node is 242 equal to the current that leaves the node. Hence, the current flow  $F_i^{(s,t)}$  through a node *i* 243 different from the source s and a target t is half of the absolute flow on the edges incident 244 in *i*: 245

$$F_i^{(s,t)} = \frac{1}{2} \sum_j A_{i,j} |v_i^{(s,t)} - v_j^{(s,t)}|$$

246

Moreover, the current flows  $F_s^{(s,t)}$  and  $F_t^{(s,t)}$  through both *s* and *t* are set to 1, if 24 end-points of a path are considered part of the path, or to 0 otherwise. Since the potential 248  $v_i^{(s,t)} = G_{i,t}^+ - G_{i,t}^+$ , with  $G^+$  the generalized inverse of the graph Laplacian, the above 249 equation can be expressed in terms of elements of  $G^+$  as follows: 250

251 
$$F_i^{(s,t)} = \frac{1}{2} \sum_j A_{i,j} |G_{i,s}^+ - G_{i,t}^+ + G_{j,t}^+ - G_{j,s}^+|$$

Version July 19, 2021 submitted to Journal Not Specified

7 of 22

Finally, the current-flow betweenness centrality  $b_i$  of node *i* is the flow through *i* averaged over all source-target pairs (*s*, *t*):

$$b_i = \frac{\sum_{s < t} F_i^{(s,t)}}{(1/2)n(n-1)} \tag{9}$$

#### 2.5.4. Eigenvector Centrality 252

Eigenvector centrality is a measure of the influence a node has on a network. If a 253 node is pointed to by many nodes (which also have high Eigenvector centrality) then 254 that node will have high Eigenvector centrality. In this case, the ROI's are the nodes 255 and PET images provide the intensity value for each ROI, which helps in computing 256 the centrality values each scan. Another interpretation to the centrality measure is that 257 it provides the list of prominent regions in the brain network hierarchy and helps in 258 detection of localized differences between patient populations[52]. 259

Previous work on AD patients and comparison with normal patients provides the 260 usefulness of Eigenvector centrality[53]. 261

#### 3. Statistical Analysis 262

For this study the null hypothesis is that percolation centrality value does not 263 indicate the propagation of beta-amyloids within the brain network. 264

To determine the impact the percolation value has over each PET scan, a compar-265 ison with the regions of interest from the brain atlas is done using the Multiple linear 266 regression analysis. 267

This study is exploratory in nature, and that the multiplicity problem is significant. And implementation of multiple test procedures does not solve the problem of making 269 valid statistical inference for hypotheses that were generated by the data. But it does 270 assist in describing the possible mechanism. 271

### 3.1. Pairwise Analysis of Variance 272

To obtain pairwise group differences, we carry out a post prior (post hoc) analysis 273 using scikit-posthocs package; the Student T-test pairwise gives us the respective p 274 values. The ANOVA test is performed for each node in the network with the null 275 hypothesis that the mean percolation centrality of that node is the same across the three 276 stages. To test the null hypothesis, Analysis of variance with significance level ( $\alpha$ ) of 0.05 277 is used. 278

#### 3.2. Error Correction 279

To control for multiple comparisons of 121 nodes, the Scheffe Test and control 280 for Experiment-wise Error Rate (EER) is carried out. It is a single-step procedure that 281 calculates the simultaneous confidence intervals for all pairwise differences between 282 means. 283

#### 3.3. Multivariate Linear Regression 284

A correlation between the percolation centrality values for all 121 nodes and psy-285 chometric test scores - MMSE and NPIQ - is computed to identify the regions of interest 286 that can be used as reliable predictors. Instead of performing multiple correlations across all three diagnoses, a multivariate regression analysis using regularisation techniques, 288 wherein the features are the nodal percolation centrality values, and the target variable 289 is the MMSE or NPIQ score. The goal is not to build a predictive model but to use it 290 to quantify each node's influence in distinguishing between the clinical conditions for 291 interpretation purposes. Had the purpose been building a machine learning model, it 292 would imply the need to develop elaborate features sets (more than just percolation 293 centrality) and utilize complex machine learning architectures (which provide less room for interpretability) 295

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

### 296 3.4. Regularization and Cross-Validation

We use regularization in our multivariate linear regression (MLR) to make sure our 297 regression model generalizes better to unseen data. Regularization is necessary to control for overfitting. Here, both Lasso regression (L1 penalty) as well as Ridge regression 200 (L2 penalty) are tested, and both provide similar root mean squared errors (RMSE) and similar desired results. We choose Lasso with  $\alpha = 0.1$ , for reporting our results (Figure 6). 301 To quantify the robustness and reliability of our model, before and after regularization, 302 we perform a leave one out cross-validation (LOOCV). We choose this cross-validation 303 strategy because it is unbiased and better suited to our smaller sample sizes (especially in PiB tracer subset). We observe an improvement in validation RMSE with an increase in 305 regularization (parameter  $\alpha$ ), but we also observe that excessive penalization of weights 306 at very high values of  $\alpha$  can result in the regression model converging to the mean of 307 the output MMSE/NPIQ scores. To take this into account, we also plot the standard 308 deviation in predicted MMSE/NPIQ outputs and choose  $\alpha = 1$  for sufficient but not 309 excessive regularization (Further details in supplementary figures). 310

311 4. Results

### 312 4.1. Pairwise ANOVA

The student t-test is performed on the resulting five centrality values for each tracer type and clinical conditions. There was a significant effect of the beta-amyloid accumulation on the five centrality values at p<0.05 level for the three clinical groups[F(3, 454) = 3.002 for AV45 and F(3, 97) = 3.027 for PiB] (Table 2). A one-way between clinical groups ANOVA was conducted to compare the effect of beta-amyloid accumulation/tau protein on five centrality values in the cognitive normal, mild cognitive impairment and Alzheimer's disease patient(Table 3 & Table 4)).

### 4.1.1. Cross-Validation and Regularization

Increasing regularization ( $\alpha$ ) improves the validation RMSE, making it more robust and generalize to unseen data. But at higher values of  $\alpha$ , it is observed that the standard deviation of predicted MMSE scores decreases to less than < 2, irrespective of clinical condition. Which could mean that it saturates to predicting the mean MMSE value when regression weights are extremely penalized. Thereby choosing a reasonably small yet effective  $\alpha$  value (less than 2), for which the validation RMSE and the standard deviation in output predicted MMSE.

### 328 4.2. Multivariate Linear regression

A linear regression model between the percolation centrality values for all 121 nodes and psychometric test scores - MMSE and NPIQ - is computed to identify the regions of interests that can be used as reliable predictors(Figure 4). Instead of performing multiple correlations across all three diagnoses, a multivariate regression analysis using leave one out cross validation is carried out, wherein the features are the nodal percolation centrality values and the target variable are the psychological assessment scores(Table 6 & Table 7).

### **4.3.** Comparison of Threshold Schemes

The two schemes are compared on the number of ROI's that can be considered 337 on the basis of ANOVA analysis( $p \le 0.05$ ), The Juelich atlas has five clusters; frontal, 338 parietal, temporal, occipital lobes and the white matter regions. As well as com- paring 339 the performance of the threshold schemes between the two tracers(Table 5). Orthogonal 340 Minimum Spanning Tree: provides a total of 112 ROI's across the five nodal metrics. 341 On the Basis of the tracers, 60 ROI's are obtained for AV45 and 52 for PiB. Further, the 342 ranking of ROI on the basis of the threshold scheme is listed for the three clinical groups 343 for the respective tracers 344

Version July 19, 2021 submitted to Journal Not Specified

Shortest Path Threshold: here a total of 66 ROI's are obtained. 31 and 35 for AV45 345 and PiB tracers respectively. On the basis of the collective influence algorithm the ROI's 346 are ranked for the three clinical groups and their respective tracers. 34

Further, comparing the number of statistically valid(MLR) ROIs across the five 348 centrality values with the psychometric tests; MMSE and NPI-Q is performed. This 349 helps in comparing the function of the ROI with the assessment carried out on the 350 test(Table 5 Also see supplementary material-Tables 11 through 18). 351

### 4.4. Other Graph Metrics 352

The Closeness Centrality provides the highest number of ROI's across overall(Table 353 10); 80 in total. Eigenvector Centrality provides 33 ROI's(Table 9), whereas Percolation 354 Centrality has 24 ROI's followed by the Betweenness Centrality measure with a total of 355 23 ROI's and Current Flow Betweenness Centrality 19 ROI's across the two tracers(Table 356 8). 357

### 4.5. Collective Influence Ranking 358

The collective influence algorithm ranks the ROIs; here, the rank list is generated 359 for the two tracers- AV45 and PiB. When a comparison of the rank is carried out between 360 the clinical groups and tracers in the case of PiB, the ranking increases when moving 361 from CN clinical condition to MCI, and then ranking decreases going from MCI to AD. 362 Overall the ranking increases by 50% from cognitively normal condition to Alzheimer's 363 disease condition. 36

### 4.6. Demographics 365

On the basis of the selection criteria, 531 patients were available for this study. Of 366 this, 48% of the females were of the Cognitively Normal group, 25% with Mild cognitive 367 impairment, and 27% with Alzheimer's disease. 368

43% of the patients received more than 12 years of education as opposed to only 16% who received less than 12 years of education, 31% received more than 12 years of 370 education in the MCI group as opposed to 69% with less than 12 years of education. 371

47% of the Left-handed patients were in the AD clinical group as opposed to 26% 372 in the right-handed patients. One patient in the MCI, two in CN, and four in AD groups 373 were multilingual. 374

4.7. Figures, Tables and Schemes 375



Figure 1. Generic example of a Percolation Network and Percolation Centrality

Version July 19, 2021 submitted to Journal Not Specified



Figure 2. PET image preprocessing flowchart.



Figure 3. Analysis Pipeline



Figure 4. A connected network of all the nodes using the Julich Atlas. Green circles indicate the ROIs, the connecting lines indicate the edges with their weights as denoted by the accompanying color bar

Version July 19, 2021 submitted to Journal Not Specified



**Figure 5.** Illustrates the ROIs that corresponds to MMSE and NPIQ. The green circles represent ROIs associated with the MMSE psychometric assessment, the red circles represent ROIs associated with the NPIQ psychometric assessment, and the blue circles represent ROIs associated with both MMSE and NPIQ



Figure 6. Regularization using Lasso regression with L1 penalty.

Table 1:	Distribution	of	patients
----------	--------------	----	----------

	CN	MCI AD		AD	
AV45	PiB	AV45	PiB	AV45	PiB
262	13	76	65	116	19
M - 122	M - 8	M - 54	M - 45	M - 67	M - 11
F - 140	F - 5	F - 22	F - 20	F - 49	F - 8
Total - 27	75; M - 130, F - 145	Total - 1	41; M - 99, F - 42	Total - 1	35; M - 78, F - 57

Table 2: Number of Scans per tracer type and corresponding critical F-values

Tracer	AV45	PiB
No. of scans	454	97
<b>Critical F-value</b>	3.002	3.027

376 CN: Cognitively Normal, MCI: Mild Cognitive Impairment, AD: Alzheimer's Disease, M: Male, F:377 Female

Version July 19, 2021 submitted to Journal Not Specified

12 of 22

Tracer Type		AV45 PiB				
Thresholding scheme	ROI	f-value	p-value	ROI	f-value	p-value
	GM Premo- tor cortex BA6 R	5.94059	0.00283	GM Broca's area BA45 R	5.17524	0.00738
	GM Hip- pocampus subiculum L	4.96072	0.00738	GM Broca's area BA45 L	4.75064	0.01083
	GM Visual cortex V5 L	4.39253	0.01288	GM Ante- rior intra- parietal sulcus hIP3 R	3.79312	0.02605
	GM Superior parietal lob- ule 7M L	4.34316	0.01352	GM Broca's area BA44 L	3.41149	0.03713
	GM Primary motor cortex BA4a L	3.73311	0.02463	GM Mamil- lary body	3.28404	0.04182
OMST	GM Primary somatosen- sory cortex BA1 R	3.56446	0.02908			
	GM Primary auditory cor- tex TE1.2 R	3.31334	0.03725			
						0.00200
	GM Insula Ig2 L	4.58607	0.01065	GM Broca's area BA44 R	6.22323	0.00290
	WM Acous- tic radiation R	4.20148	0.01554	GM Primary auditory cor- tex TE1.2 R	5.14313	0.00759
	GM Hip- pocampus subiculum L	3.89671	0.02097	WM Cingu- lum R	4.61277	0.01227
SPT	GM Mamil- lary body	3.63729	0.02707	GM Inferior parietal lob- ule PFcm R	3.96185	0.02229
	GM Inferior parietal lob- ule Pga R	3.04114	0.04872			

Table 3: Pairwise ANOVA	for AV45 & PiB t	tracers for Betweenness	6 Centrality

Version July 19, 2021 submitted to Journal Not Specified

13 of 22

Tracer Type	AV45			PiB		
Thresholding scheme	ROI	f-value	p-value	ROI	f-value	p-value
	GM Premotor cortex BA6 R	5.87528	0.00302	GM Broca's area BA45 R	5.14527	0.00758
	GM Hip- pocampus subiculum L	4.85879	0.00815	GM Broca's area BA45 L	4.82934	0.01008
	GM Superior parietal lobule 7M L	4.48843	0.01172	GM Anterior intra-parietal sulcus hIP3 R	3.87541	0.02414
	GM Visual cortex V5 L	4.38407	0.01299	GM Broca's area BA44 L	3.42666	0.03661
	GM Anterior intra-parietal sulcus hIP1 L	4.14044	0.01650	GM Mamil- lary body	3.33030	0.04005
	GM Superior parietal lobule 7P R	3.83170	0.02235			
	GM Primary motor cortex BA4a L	3.77499	0.02364			
OMST	GM Primary somatosen- sory cortex BA1 R	3.65131	0.02670			
	GM Primary auditory cor- tex TE1.2 R	3.34477	0.03611			
	GM Insula Ig2 L	4.64660	0.01004	GM Broca's area BA44 R	6.30152	0.00270
	WM Acoustic radiation R	4.38388	0.01299	GM Primary auditory cor- tex TE1.2 R	5.03631	0.00836
	GM Hip- pocampus subiculum L	3.93752	0.02014	WM Cingu- lum R	4.57068	0.01275
	GM Mamil- lary body	3.54618	0.02961	GM Inferior parietal lobule PFcm R	3.94533	0.02263
SPT	GM Inferior parietal lobule Pga R	3.17572	0.04266			
	GM Lateral geniculate body L	3.05960	0.04784			

# Table 4: Pairwise ANOVA for AV45 & PiB tracers for Percolation Centrality

Version July 19, 2021 submitted to Journal Not Specified

14 of 22

Threshold Scheme	OM	ST	SPT		
Tracer/ Centrality Measure	AV45	PiB	AV45	PiB	
BC	9	5	5	4	
CC	33	29	10	6	
CFBC	5	2	1	12	
EVC	4	11	9	9	
PC	9	5	6	4	

Table 5: Distribution of ROI's across graph metrics and tracer type on the basis of ANOVA test.

BC: Betweenness Centrality, CC: Closeness Centrality, CFBC: Current Flow Betweenness Centrality, EVC:

Eigenvector Centrality and PC: Percolation Centrality 379

380

378

Table 6: Multivariate Linear Regression Analysis- Number of Region of Interest Across Clinical Conditions for Both Threshold Schemes for Betweenness Centrality

Clinical Condition			CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
-	MMSE	AV45	4	5	13	8	4	7
Batwoonnoss Contrality		PiB	5	4	5	1	2	9
betweenness Centrainty	NPLO	AV45	0	3	1	1	0	0
	INPI-Q	PiB	2	14	1	0	3	10

Table 7: Multivariate Linear Regression Analysis- Number of Region of Interest Across Clinical Conditions for Both Threshold Schemes for Percolation Centrality

Clinical Condition		ondition	CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
	MMSE	AV45	4	6	12	2	4	7
Porcolation Controlity		PiB	5	3	5	0	2	9
recolation centrality	NPLO	AV45	6	3	2	1	0	0
	LALL Q	PiB	2	14	0	1	3	10

PT: Psychometric Assessment, OMST: Orthogonal Minimum Spanning Tree, SPT: Shortest Path Thresh-381 old, MMSE: Mini Mental State Examination, NPIQ: Neuropsychiatric Inventory Questionnaire Questionnaire 382

383

### 5. Discussion 384

Here, a comparison of five nodal metrics; Betweenness centrality, closeness central-385 ity, current flow betweenness centrality, Eigenvector centrality, and percolation centrality, 386 is carried out to better understand the study. Based on the variance analysis and multi-387 variate regression testing and the percolation centrality graph metric computed using the PET images, it is possible to show Alzheimer's disease progressing through the 389 beta-amyloid/tau protein networks. 390

The student t-test provides nodes for each of the five centrality measures across the 391 three clinical conditions, tracer types, and threshold schemes. Here, only the Current 392 Flow Betweenness Centrality Measure fails to provide ROIs across all conditions (see 393 tables 6 through 10), provides only three in cognitively normal condition and two in a 394 mild cognitively impaired condition, both using the OMST scheme for threshold. 395

It is observed that percolation centrality values of certain areas of the brain, such 396 as inferior and superior parietal lobules, are reliable for the tracer PiB. In contrast, for 397 most other cases, the brain areas differ for each tracer considerably. The variation due 398

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license

Version July 19, 2021 submitted to Journal Not Specified

15 of 22

to the tracers could be because AV45 and PiB bind to the amyloids differently. It is also

observed that the percolation centrality of Broca's area is a reliable differentiator between
 C.N. and A.D. clinical conditions, which validates previous findings that cognitive

<sup>402</sup> impairment affects speech production[54].

The MLR analysis for each of the centrality measures across the clinical conditions for both the tracer types provides, on average, one to two ROIs across conditions that can be considered as markers for studying Alzheimer's disease. Expect the current flow betweenness centrality measure, which performed poorly in this study providing only four(3-CN, 1-MCI) ROIs for both the threshold schemes and only one(MCI) ROI for AV45 and PiB tracers, respectively.

Further, when MLR is carried out for the NPI questionnaire, it provides fewer ROIs for each of the centrality measures. When comparing the contribution of ROIs for MMSE-related tasks and NPIQ related tasks. Percolation centrality has the highest percentage of 41% of ROIs. Followed by Closeness centrality with 40.5%, Betweenness centrality with 30%.

The results from the Scheffe test provide a means to validate and increase the confidence in the results—the leave one out cross-validation (LOOCV) strategy to test the robustness and reliability of our regression. Here cross-validation strategy is implemented because it is unbiased and better suited to our smaller sample size. Using the regularization (L1 - Lasso or L2 - Ridge) to control for overfitting, it is observed that increasing regularization on validation RMSE.

The ROIs obtained from the pairwise t-test for between the clinical conditions show
that the OMST scheme provides a higher number of valid ROIs across the five centrality
measures. In comparison between the two tracer types and threshold schemes, AV45
provides 92 ROIs, whereas PiB gives 88 ROIs. Of this, 33.7% and 39.8% of the ROIs are
based on the Shortest Path threshold scheme.

Previous studies show that the seeding of amyloid-beta occurs in neocortical and
subcortical regions[55]; from this study, it is observed that for PiB, the following ROI W.M. Superior occipito-frontal fascicle R is part of both the neocortical and subcortical
regions of the brain. Apart from this, AV45 tracer has G.M. Medial geniculate body L
ROI in the subcortical region and the following in the neocortical region -G.M. Superior
parietal lobule 7P L, G.M. Anterior intra-parietal sulcus hIP3 R, G.M. Superior parietal
lobule 7A L, and G.M. Superior parietal lobule 5L L, these are picked up with OMST
scheme across all conditions when compared to SPT.

Prior research shows that damage to the parietal lobe is common in A.D., which can
lead to apraxia[54,56], which is attested by these results. A.D. is associated with atrophy
of the cornu ammonis, the subfield of the hippocampus, and deficits in episodic memory
and spatial orientation[57–59]

And the following in the subcortical region - GM Amygdala-laterobasal group L, GM Amygdala-laterobasal group R and GM Hippocampus hippocampal- amygdaloid transition area R. Age factor not so important but the presence of beta amyloid deposits is[60], Since these ROIs stand out irrespective of the clinical condition or demographic backgrounds, the percolation centrality has a potential to be a reliable value for AD diagnosis, these ROIs are picked up by both tracers and threshold schemes.

Recent methods include genetic and protein markers to improve predicting the course of the disease[61], Genetic testing[62]for markers of A.D., the apolipoprotein-e4 (APOE-e4)[63], or the use of blood testing or brain imaging to rule out dementia due to other factors. These methods rely on many data points and equally reliable computing hardware; this is currently a challenge.

Given that A.D. diagnosis is a global challenge, a method that works well in a spectrum of nations, from developed countries such as the United States to rural hospitals of southeast Asia or Africa[2] is necessary. Methods such as principal component analysis have a few drawbacks; for instance, choosing the number of principal components and data standardization for multiple PET scans of patients with different tracers leads

Version July 19, 2021 submitted to Journal Not Specified

to controlling multiple variables. Or using regression analysis which is based on the 453 assumption that there are cause and effect in place. Furthermore, a relationship that is 454

present within a limited data set might get overturned with a detailed data set.

5.0.1. Limitations 456

This study does not give any evidence regarding the disease progression in terms 457 of the ROIs or patient clinical group. However, this can be addressed by increasing the number of observations within each patient clinical group. 459

The PET tracers used for acquiring the images, Pittsburgh Compound B (PiB) and 460 Florbetapir (AV45), are compared to check for which among the two tracers provide 461 a more consistent or reliable PCv. Here, the AV45 tracer binds with a high affinity to 462 the beta-amyloid plaque, whereas PiB binds to oligomers or protofibrils. A possible 463 explanation for the difference in PCv generated using these tracers would be their 464 binding targets. The use of second-generation tracers can help improve the accuracy and 465 test the applicability of percolation centrality on other neurodegenerative diseases and the possibility of using it in metastatic cancer scenarios. 467

Expanding the dataset to include more patients and comprehensive data that factors 468 in healthy aging shrinkage of the brain, which results in a decrease of the distances of 469 the brain networks, can help improve the reliability of the percolation centrality value. 470 This can then provide a setting for testing out other psychological assessments that can 471 be used as early indicators for dementia due to Alzheimer's disease, thereby tailoring it 472 to specific demographics or population subsets. 473

The current pipeline is built for tracers such as AV45 and PiB, which indicate beta-474 amyloid plaque concentrations directly and as a post-hoc implementation. However, the pipeline can work with second-generation tracers and tracers like FDG with some 476 appropriate modifications, namely: taking the multiplicative inverse of the percolation 477 states of each of the ROIs to reflect the behavior of the FDG tracer. 478

A comparison of the ROIs across clinical conditions and tracers does not provide 479 any new information at this stage regarding a common or group of common ROIs across 480 the data(see Table 6. and 7.). 481

### 6. Conclusions 482

This study shows that percolation centrality is a reliable predictor and identifies 483 the nodes that regulate the movement of beta-amyloid plaque and use them to track the 484 disease 485

This work demonstrates that using the existing neuroimaging method, PET-CT, 186 can add value with relatively short computation time provided sufficient hardware 487 capability is present. The ability to provide a metric to the extent of the disease state is 488 advantageous to the current world of Alzheimer's. Prolonging life with modern-day 489 medicine pushes patients to a world of medical experiences that deviate from the normal. 490 Being able to show the deviation with a value such as percolation centrality has potential 491 applications. 492

The reliability of percolation centrality can be improved by addressing the concerns 493 that arise by the factors such as the number of patients and the number of patients within 101 each clinical group, time points of data collection, demographics, and the PET tracers used were the limiting factors. Thus, this study provides the usability of percolation 496 centrality value to determine the patient's state and sets the stage for studying other 497 neurodegenerative diseases. 498

Unlike measures such as hub centrality or betweenness centrality, which provide information regarding a vital vertex/node within a network, the collective influence algo-500 rithm provides a minimum set of nodes of the network that are key to the beta-amyloid 501 plaque movement, which can provide information regarding a particular pathway that 502 is susceptible to the neuropathology. 503

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

17 of 22

The threshold schemes implemented in this study indicate that a data-driven approach such as the Orthogonal Minimum Spanning Tree provides better results compared to the Shortest Path approach. Finally, we rank the ROIs based on influence in the network using the CI algorithm. We compare the results on two thresholding approaches, SPT and OMST, along with finding the influential nodes; this will help us gauge the reliability across different threshold schemes. CI algorithm gives a ranked list of influential nodes for each network (or each scan).

The rank of a node is then further calculated for each category as the sum of 511 individuals ranks of that node for every scan-wise list, divided by the number of scans 512 it occurs in. Nodes are then ranked accordingly in a given category. This provides a 513 general ranking of nodes in a category (AD/MCI/CN) instead of looking at influential 514 nodes in each scan separately. The results differ slightly based on the thresholding 515 scheme adopted but broadly align with MLR results discussed earlier. Since this is an 516 exploratory study, improving robustness across different thresholding schemes can be a 517 possible future work. 518

Supplementary Materials: Please follow the link https://www.mdpi.com//1/1/0/https://
 github.com/raghavprasad13/ADNI-Projectfor the analysis pipeline code,

- and follow this link https://www.mdpi.com//1/1/0/https://drive.google.com/file/d/1ZIVb6
- TFyJt68wb\_N8mWgBr3xuhOcdZem/view?usp=sharing for Tables 11 through 18.

Author Contributions: Conceptualization, Gautam and Veeky; methodology, Raghav and Gautam; validation, Gautam, Raghav and Pranav; formal analysis, Gautam, Raghav and Pranav;
 resources, Veeky Baths; data curation, Gautam and Raghav; writing—original draft preparation,
 Gautam; writing—review and editing, Gautam, Raghav, Pranav and Veeky; visualization, Raghav
 and Gautam; supervision, Veeky Baths; All authors have read and agreed to the published version
 of the manuscript.

**Funding:** This research received no funding.

530 Institutional Review Board Statement: Institutional Review Board Waiver Statement- Informed

consent from the patients is obtained before the assessment carried out by the ADNI study team

(See ADNI website for details), and this study is a secondary data analysis of the ADNI data
 collection, which aims at providing a simplified metric to an already diagnosed patient. The data

access and usage is within the ADNI data use agreements.

Informed Consent Statement: Informed consent was obtained from all patients involved in thestudy by ADNI study Team(s).

- 537 Data Availability Statement: PET images from ADNI database are used in this study.
- **538** Conflicts of Interest: The authors declare no conflict of interest.
- 539 Abbreviations
- <sup>540</sup> The following abbreviations are used in this manuscript:
- 541

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

18 of 22

	AD	Alzheimer Disease
	ANOVA	Analysis of Variance
	AV45	Florbetapir (18F- AV-45)
	CI	Collective Influence
	CN	Cognitively Normal
	CSF	Cerebrospinal Fluid
	DOF	Degrees of Freedom
	EEG	Electroencephalography
	FAB	Frontal Assessment Battery
	fMRI	functional Magnetic Resonance Imaging
	FSL	FMRIB Software Library
542	GNU	GNU's Not Unix
	PCv	Percolation Centrality Value
	PET	Positron Emission tomography
	PiB	Pittsburgh compound B (11C-PIB)
	RMSE	Root Mean Square Error
	MCI	Mild Cognitive Impairment
	MEG	Magnetoencephalography
	MLR	Multivariate Linear Regression
	MMSE	Mini-Mental State Examination
	MST	Minimum Spanning Tree
	NPIQ	Neuropsychiatric Inventory Questionnaire
	OMST	Orthogonal Minimum Spanning Tree
		- 9

### 543 Appendix A.

544 Appendix A.1. Percolation Centrality Computation

The percolation centrality value is calculated for each network using the inbuilt function of Networkx. This has a worst-case time complexity of  $O(n^3)$ , where n is the number of nodes in the network. Using a modified form of Brandes' fast algorithm for betweenness centrality, the complexity can be reduced to O(nm), where m is the number of edges. However, percolation centrality calculation with target nodes cannot take advantage of this optimization and has a worst-case time complexity of  $O(n^3)$ 

<sup>551</sup> Appendix A.2. Other Graph Metrics-Tables

 Table 8: Multivariate Linear Regression Analysis- Region of Interest Across Clinical

 Conditions for Both Threshold Schemes for Current Flow Betweenness Centrality

Clinical Condition		CN		MCI		AD		
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Current Flow Betweenness Centrality	MMSE	AV45	3	0	1	0	0	0
	WIWIJE	PiB	0	0	1	0	0	0
	NPL-O	AV45	0	0	0	0	0	0
	1 VI I-Q	PiB	0	0	0	0	0	0

Table 9: Multivariate Linear Regression Analysis- Region of Interest Across ClinicalConditions for Both Threshold Schemes for Eigenvector Centrality

Clinical Condition		CN	CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
	MMSE	AV45	2	2	11	4	7	10
Eigenvector		PiB	2	2	6	6	8	3
Centrality	NPL-O	AV45	1	4	1	1	0	0
	1VI 1-Q	PiB	3	0	3	3	2	9

Version July 19, 2021 submitted to Journal Not Specified

Clinical Condition			CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Closeness Centrality	MMSE	AV45	0	5	1	2	2	1
		PiB	2	4	46	0	6	0
	NPI-Q	AV45	1	0	0	2	0	0
		PiB	3	30	1	0	0	10

Table 10: Multivariate Linear Regression Analysis- Region of Interest Across Clinical Conditions for Both Threshold Schemes for Closeness Centrality

PT: Psychometric Assessment, OMST: Orthogonal Minimum Spanning Tree, SPT: Shortest Path Thresh-552

old, MMSE: Mini Mental State Examination, NPIQ: Neuropsychiatric Inventory Questionnaire Questionnaire 553

# References

- 1. El-Hayek, Y.H.; Wiley, R.E.; Khoury, C.P.; Daya, R.P.; Ballard, C.; Evans, A.R.; Karran, M.; Molinuevo, J.L.; Norton, M.; Atri, A. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease 2019, 70, 1–19. doi:10.3233/jad-190426.
- 2. 2020 Alzheimer's disease facts and figures. Alzheimer's and Dementia 2020, 16, 391-460. doi:10.1002/alz.12068.
- 3 Johnson, K.A.; Minoshima, S.; Bohnen, N.I.; Donohoe, K.J.; Foster, N.L.; Herscovitch, P.; Karlawish, J.H.; Rowe, C.C.; Carrillo, M.C.; Hartley, D.M.; Hedrick, S.; Pappas, V.; Thies, W.H. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's & dementia: the journal of the Alzheimer's Association 2013, 9, e-1-16. doi:10.1016/j.jalz.2013.01.002.
- Shaw, L.M.; Arias, J.; Blennow, K.; Galasko, D.; Molinuevo, J.L.; Salloway, S.; Schindler, S.; Carrillo, M.C.; Hendrix, J.A.; 4. Ross, A.; Illes, J.; Ramus, C.; Fifer, S. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association 2018, 14, 1505–1521. doi:10.1016/j.jalz.2018.07.220.
- Landau, S.M.; Thomas, B.A.; Thurfjell, L.; Schmidt, M.; Margolin, R.; Mintun, M.; Pontecorvo, M.; Baker, S.L.; Jagust, W.J.; 5. Initiative, A.D.N. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. European journal of nuclear medicine and molecular imaging 2014, 41, 1398-1407. doi:10.1007/s00259-014-2753-3.
- 6. Yamin, G.; Teplow, D.B. Pittsburgh Compound-B (PiB) binds amyloid  $\beta$ -protein protofibrils. Journal of neurochemistry 2017, 140, 210-215. doi:10.1111/jnc.13887.
- 7. Su, Y.; Flores, S.; Wang, G.; Hornbeck, R.C.; Speidel, B.; Joseph-Mathurin, N.; Vlassenko, A.G.; Gordon, B.A.; Koeppe, R.A.; Klunk, W.E.; Jack Jr., C.R.; Farlow, M.R.; Salloway, S.; Snider, B.J.; Berman, S.B.; Roberson, E.D.; Brosch, J.; Jimenez-Velazques, I.; van Dyck, C.H.; Galasko, D.; Yuan, S.H.; Jayadev, S.; Honig, L.S.; Gauthier, S.; Hsiung, G.Y.R.; Masellis, M.; Brooks, W.S.; Fulham, M.; Clarnette, R.; Masters, C.L.; Wallon, D.; Hannequin, D.; Dubois, B.; Pariente, J.; Sanchez-Valle, R.; Mummery, C.; Ringman, J.M.; Bottlaender, M.; Klein, G.; Milosavljevic-Ristic, S.; McDade, E.; Xiong, C.; Morris, J.C.; Bateman, R.J.; Benzinger, T.L. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2019, 11, 180–190, [https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2018.12.008]. doi:https://doi.org/10.1016/j.dadm.2018.12.008.
- Tombaugh, T.N.; McDowell, I.; Kristjansson, B.; Hubley, A.M. Mini-Mental State Examination (MMSE) and the Modified MMSE 8. (3MS): A psychometric comparison and normative data. Psychological Assessment 1996, 8, 48–59. doi:10.1037//1040-3590.8.1.48.
- Dubois, B.; Slachevsky, A.; Litvan, I.; Pillon, B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000, 55, 1621–1626. 9 doi:10.1212/wnl.55.11.1621.
- 10. Cummings, J.L.; Mega, M.; Gray, K.; Rosenberg-Thompson, S.; Carusi, D.A.; Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44, 2308–2314. doi:10.1212/wnl.44.12.2308.
- Reijneveld, J.C.; Ponten, S.C.; Berendse, H.W.; Stam, C.J. The application of graph theoretical analysis to complex networks in the 11. brain. Clinical Neurophysiology 2007, 118, 2317-2331. doi:10.1016/j.clinph.2007.08.010.
- 12. Stam, C.J.; Reijneveld, J.C. Graph theoretical analysis of complex networks in the brain, 2007. doi:10.1186/1753-4631-1-3.
- 13. Sakkalis, V. Modern electroencephalographic assessment techniques: Theory and applications; 2014; pp. 1–383. doi:10.1007/978-1-4939-1298-8.
- 14. Vecchio, F.; Miraglia, F.; Maria Rossini, P. Connectome: Graph theory application in functional brain network architecture. Clinical Neurophysiology Practice 2017, 2, 206–213. doi:10.1016/j.cnp.2017.09.003.
- de Haan, W.; Mott, K.; van Straaten, E.C.; Scheltens, P.; Stam, C.J. Activity Dependent Degeneration Explains Hub Vulnerability in 15. Alzheimer's Disease. PLoS Computational Biology 2012, 8, [arXiv:10.1371/journal.pcbi.1002582]. doi:10.1371/journal.pcbi.1002582.
- 16. Tijms, B.M.; Wink, A.M.; de Haan, W.; van der Flier, W.M.; Stam, C.J.; Scheltens, P.; Barkhof, F. Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of Aging 2013, 34, 2023–2036. doi:10.1016/j.neurobiolaging.2013.02.020.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

20 of 22

- 17. Tijms, B.M.; Wink, A.M.; de Haan, W.; van der Flier, W.M.; Stam, C.J.; Scheltens, P.; Barkhof, F. Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging* **2013**, *34*, 2023–2036. doi:10.1016/j.neurobiolaging.2013.02.020.
- 18. Wook Yoo, S.; Han, C.E.; Shin, J.S.; Won Seo, S.; Na, D.L.; Kaiser, M.; Jeong, Y.; Seong, J.K. A network flow-based analysis of cognitive reserve in normal ageing and Alzheimer's disease. *Scientific Reports* **2015**, *5*, 1–14. doi:10.1038/srep10057.
- 19. Chung, J.; Yoo, K.; Kim, E.; Na, D.L.; Jeong, Y. Glucose Metabolic Brain Networks in Early-Onset vs. Late-Onset Alzheimer's Disease , 2016.
- 20. Son, S.J.; Kim, J.; Seo, J.; min Lee, J.; Park, H. Connectivity analysis of normal and mild cognitive impairment patients based on FDG and PiB-PET images. *Neuroscience Research* **2015**, *98*, 50–58. doi:10.1016/j.neures.2015.04.002.
- 21. Klyuzhin, I.S.; Fu, J.F.; Hong, A.; Sacheli, M.; Shenkov, N.; Matarazzo, M.; Rahmim, A.; Jon Stoessl, A.; Sossi, V. Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. *PLoS ONE* **2018**, *13*, 1–20. doi:10.1371/journal.pone.0206607.
- 22. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.J.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; Mohs, R.C.; Morris, J.C.; Rossor, M.N.; Scheltens, P.; Carrillo, M.C.; Thies, B.; Weintraub, S.; Phelps, C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2011, 7, 263–269. doi:10.1016/j.jalz.2011.03.005.
- 23. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R.J.; Kaye, J.; Montine, T.J.; Park, D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M.V.; Phelps, C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2011, 7, 280–292. doi:10.1016/j.jalz.2011.03.003.
- Kötter, R.; Mazziotta, J.; Toga, A.; Evans, A.; Fox, P.; Lancaster, J.; Zilles, K.; Woods, R.; Paus, T.; Simpson, G.; Pike, B.; Holmes, C.; Collins, L.; Thompson, P.; MacDonald, D.; Iacoboni, M.; Schormann, T.; Amunts, K.; Palomero-Gallagher, N.; Geyer, S.; Parsons, L.; Narr, K.; Kabani, N.; Goualher, G.L.; Boomsma, D.; Cannon, T.; Kawashima, R.; Mazoyer, B. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences* 2001, 356, 1293–1322. doi:10.1098/rstb.2001.0915.
- 25. Eickhoff, S.B.; Stephan, K.E.; Mohlberg, H.; Grefkes, C.; Fink, G.R.; Amunts, K.; Zilles, K. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *NeuroImage* 2005, 25, 1325–1335. doi:10.1016/j.neuroimage.2004.12.034.
- Desikan, R.S.; Ségonne, F.; Fischl, B.; Quinn, B.T.; Dickerson, B.C.; Blacker, D.; Buckner, R.L.; Dale, A.M.; Maguire, R.P.; Hyman, B.T.; Albert, M.S.; Killiany, R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* 2006, *31*, 968–980. doi:10.1016/j.neuroimage.2006.01.021.
- 27. Newman, M.E.; Watts, D.J. Scaling and percolation in the small-world network model. *Physical Review E Statistical Physics, Plasmas, Fluids, and Related Interdisciplinary Topics* **1999**, *60*, 7332–7342, [arXiv:cond-mat/9904419]. doi:10.1103/PhysRevE.60.7332.
- 28. Piraveenan, M.; Prokopenko, M.; Hossain, L. Percolation Centrality: Quantifying Graph-Theoretic Impact of Nodes during Percolation in Networks. *PLOS ONE* **2013**, *8*, e53095.
- 29. Moore, C.; Newman, M.E.J. Epidemics and percolation in small-world networks. *Physical Review E* 2000, *61*, 5678–5682. doi:10.1103/PhysRevE.61.5678.
- 30. Newman, M.E.J. Spread of epidemic disease on networks. Physical Review E 2002, 66, 16128. doi:10.1103/PhysRevE.66.016128.
- 31. Sander, L.M.; Warren, C.P.; Sokolov, I.M.; Simon, C.; Koopman, J. Percolation on heterogeneous networks as a model for epidemics. *Mathematical biosciences* **2002**, *180*, 293–305. doi:10.1016/s0025-5564(02)00117-7.
- Del Ferraro, G.; Moreno, A.; Min, B.; Morone, F.; Pérez-Ramírez, Ú.; Pérez-Cervera, L.; Parra, L.C.; Holodny, A.; Canals, S.; Makse, H.A. Finding influential nodes for integration in brain networks using optimal percolation theory. *Nature Communications* 2018, 9, [1806.07903]. doi:10.1038/s41467-018-04718-3.
- 33. Morone, F.; Min, B.; Bo, L.; Mari, R.; Makse, H.A. Collective Influence Algorithm to find influencers via optimal percolation in massively large social media. *Scientific reports* **2016**, *6*, 30062. doi:10.1038/srep30062.
- 34. Chopra, A.; Shan, L.; Eckelman, W.C.; Leung, K.; Latterner, M.; Bryant, S.H.; Menkens, A. Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress. *Molecular imaging and biology* **2012**, *14*, 4–13. doi:10.1007/s11307-011-0521-3.
- 35. Jenkinson, M.; Beckmann, C.F.; Behrens, T.E.J.; Woolrich, M.W.; Smith, S.M. FSL. *NeuroImage* 2012, *62*, 782–790. doi:10.1016/j.neuroimage.2011.09.015.
- 36. Initiative, A.D.N. PET Acquisition 2017.
- 37. Jenkinson, M.; Bannister, P.; Brady, M.; Smith, S. Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images. *NeuroImage* **2002**, *17*, 825 841. doi:https://doi.org/10.1006/nimg.2002.1132.
- 38. Vizza, P.; Tradigo, G.; Messina, D.; Cascini, G.L.; Veltri, P. Methodologies for the analysis and classification of PET neuroimages. *Network Modeling Analysis in Health Informatics and Bioinformatics* **2013**, *2*, 191–208. doi:10.1007/s13721-013-0035-9.
- 39. Reuter, M.; Schmansky, N.J.; Rosas, H.D.; Fischl, B. Within-subject template estimation for unbiased longitudinal image analysis. *NeuroImage* **2012**, *61*, 1402–1418. doi:10.1016/j.neuroimage.2012.02.084.

Version July 19, 2021 submitted to Journal Not Specified

21 of 22

- 40. Tange, O. GNU Parallel 20200722 ('Privacy Shield') **2020.** GNU Parallel is a general parallelizer to run multiple serial command line programs in parallel without changing them., doi:10.5281/zenodo.3956817.
- 41. Sanchez-Romero, R.; Cole, M.W. Combining multiple functional connectivity methods to improve causal inferences. *bioRxiv* **2020**, [https://www.biorxiv.org/content/early/2020/02/06/841890.full.pdf]. doi:10.1101/841890.
- 42. Madigan, D. Graphical models in applied multivariate statistics, by J. Whittaker, John Wiley & Sons, New York, 1990, 448 pp. Price: \$59.95. *Networks* **1994**, *24*, 125. doi:10.1002/net.3230240213.
- 43. Kim, S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. *Communications for Statistical Applications and Methods* **2015**, *22*, 665–674. doi:10.5351/CSAM.2015.22.6.665.
- 44. Dimitriadis, S.I.; Salis, C.; Tarnanas, I.; Linden, D.E. Topological Filtering of Dynamic Functional Brain Networks Unfolds Informative Chronnectomics: A Novel Data-Driven Thresholding Scheme Based on Orthogonal Minimal Spanning Trees (OMSTs) , 2017.
- 45. Dimitriadis, S.I.; Antonakakis, M.; Simos, P.; Fletcher, J.M.; Papanicolaou, A.C. Data-Driven Topological Filtering Based on Orthogonal Minimal Spanning Trees: Application to Multigroup Magnetoencephalography Resting-State Connectivity. *Brain connectivity* **2017**, *7*, 661–670. doi:10.1089/brain.2017.0512.
- 46. Dimitriadis, S.I.; Laskaris, N.A.; Tsirka, V.; Vourkas, M.; Micheloyannis, S.; Fotopoulos, S. Tracking brain dynamics via timedependent network analysis. *Journal of Neuroscience Methods* **2010**, *193*, 145–155. doi:https://doi.org/10.1016/j.jneumeth.2010.08.027.
- 47. Hagberg, A.A.; Schult, D.A.; Swart, P.J. Exploring Network Structure, Dynamics, and Function using NetworkX. Proceedings of the 7th Python in Science Conference; Varoquaux, G.; Vaught, T.; Millman, J., Eds.; , 2008; pp. 11–15.
- 48. Bollobás, B.; Bollobás, B.; Riordan, O.; Riordan, O. Percolation; Cambridge University Press, 2006.
- 49. Morone, F.; Makse, H.A. Influence maximization in complex networks through optimal percolation. *Nature* **2015**, *524*, 65–68.
- 50. Richardson, M.; Domingos, P. Mining Knowledge-Sharing Sites for Viral Marketing. Proceedings of the Eighth ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; Association for Computing Machinery: New York, NY, USA, 2002; KDD '02, p. 61–70. doi:10.1145/775047.775057.
- 51. Pastor-Satorras, R.; Vespignani, A. Epidemic Spreading in Scale-Free Networks. *Phys. Rev. Lett.* 2001, *86*, 3200–3203. doi:10.1103/PhysRevLett.86.3200.
- 52. Wink, A.M. Eigenvector Centrality Dynamics From Resting-State fMRI: Gender and Age Differences in Healthy Subjects. *Frontiers in Neuroscience* **2019**, *13*, 648. doi:10.3389/fnins.2019.00648.
- 53. Wink, A.M.; Tijms, B.M.; ten Kate, M.; Raspor, E.; de Munck, J.C.; Altena, E.; Ecay-Torres, M.; Clerigue, M.; Estanga, A.; Garcia-Sebastian, M.; Izagirre, A.; Martinez-Lage Alvarez, P.; Villanua, J.; Barkhof, F.; Sanz-Arigita, E. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. *Brain and Behavior* **2018**, *8*, e01080, [https://onlinelibrary.wiley.com/doi/pdf/10.1002/brb3.1080]. doi:https://doi.org/10.1002/brb3.1080.
- 54. Fernández, M.; Gobartt, A.L.; Balañá, M.; Group, C.S. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. *BMC neurology* **2010**, *10*, 87. doi:10.1186/1471-2377-10-87.
- 55. Jucker, M.; Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* **2013**, *501*, 45–51. doi:10.1038/nature12481.
- 56. Kueper, J.K.; Speechley, M.; Lingum, N.R.; Montero-Odasso, M. Motor function and incident dementia: a systematic review and meta-analysis. *Age and Ageing* **2017**, *46*, 729–738. doi:10.1093/ageing/afx084.
- 57. Adler, D.H.; Wisse, L.E.; Ittyerah, R.; Pluta, J.B.; Ding, S.L.; Xie, L.; Wang, J.; Kadivar, S.; Robinson, J.L.; Schuck, T.; Trojanowski, J.Q.; Grossman, M.; Detre, J.A.; Elliott, M.A.; Toledo, J.B.; Liu, W.; Pickup, S.; Miller, M.I.; Das, S.R.; Wolk, D.A.; Yushkevich, P.A. Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. *Proceedings of the National Academy of Sciences of the United States of America* 2018, 115, 4252–4257. doi:10.1073/pnas.1801093115.
- 58. Masurkar, A.V. Towards a circuit-level understanding of hippocampal CA1 dysfunction in Alzheimer's disease across anatomical axes. *Journal of Alzheimer's disease & Parkinsonism* **2018**, *8*, 412.
- 59. Ogawa, M.; Sone, D.; Beheshti, I.; Maikusa, N.; Okita, K.; Takano, H.; Matsuda, H. Association between subfield volumes of the medial temporal lobe and cognitive assessments. *Heliyon* **2019**, *5*, e01828. doi:https://doi.org/10.1016/j.heliyon.2019.e01828.
- 60. Hamaguchi, T.; Eisele, Y.S.; Varvel, N.H.; Lamb, B.T.; Walker, L.C.; Jucker, M. The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain. *Acta Neuropathologica* **2012**, *123*, 31–37. doi:10.1007/s00401-011-0912-1.
- 61. Nichols, E.; Szoeke, C.E.; Vollset, S.E.; Abbasi, N.; Abd-Allah, F.; Abdela, J.; Aichour, M.T.E.; Akinyemi, R.O.; Alahdab, F.; Asgedom, S.W.; Awasthi, A.; Barker-Collo, S.L.; Baune, B.T.; Béjot, Y.; Belachew, A.B.; Bennett, D.A.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Brayne, C.; Carpenter, D.O.; Carvalho, F.; Catalá-López, F.; Cerin, E.; Choi, J.Y.J.; Dang, A.K.; Degefa, M.G.; Djalalinia, S.; Dubey, M.; Duken, E.E.; Edvardsson, D.; Endres, M.; Eskandarieh, S.; Faro, A.; Farzadfar, F.; Fereshtehnejad, S.M.; Fernandes, E.; Filip, I.; Fischer, F.; Gebre, A.K.; Geremew, D.; Ghasemi-Kasman, M.; Gnedovskaya, E.V.; Gupta, R.; Hachinski, V.; Hagos, T.B.; Hamidi, S.; Hankey, G.J.; Haro, J.M.; Hay, S.I.; Irvani, S.S.N.; Jha, R.P.; Jonas, J.B.; Kalani, R.; Karch, A.; Kasaeian, A.; Khader, Y.S.; Khalil, I.A.; Khan, E.A.; Khanna, T.; Khoja, T.A.; Khubchandani, J.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Koyanagi, A.; Krohn, K.J.; Logroscino, G.; Lorkowski, S.; Majdan, M.; Malekzadeh, R.; März, W.; Massano, J.; Mengistu, G.; Meretoja, A.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mokdad, A.H.; Mondello, S.; Moradi, G.; Nagel, G.; Naghavi, M.; Naik, G.; Nguyen, L.H.; Nguyen, T.H.; Nirayo, Y.L.; Nixon, M.R.; Ofori-Asenso, R.; Ogbo, F.A.; Olagunju, A.T.; Owolabi, M.O.; Panda-Jonas, S.; Passos, V.M.A.; Pereira, D.M.; Pinilla-Monsalve, G.D.; Piradov, M.A.; Pond, C.D.; Poustchi, H.; Qorbani,

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Version July 19, 2021 submitted to Journal Not Specified

M.; Radfar, A.; Reiner, R.C.; Robinson, S.R.; Roshandel, G.; Rostami, A.; Russ, T.C.; Sachdev, P.S.; Safari, H.; Safiri, S.; Sahathevan, R.; Salimi, Y.; Satpathy, M.; Sawhney, M.; Saylan, M.; Sepanlou, S.G.; Shafieesabet, A.; Shaikh, M.A.; Sahraian, M.A.; Shigematsu, M.; Shiri, R.; Shiue, I.; Silva, J.P.; Smith, M.; Sobhani, S.; Stein, D.J.; Tabarés-Seisdedos, R.; Tovani-Palone, M.R.; Tran, B.X.; Tran, T.T.; Tsegay, A.T.; Ullah, I.; Venketasubramanian, N.; Vlassov, V.; Wang, Y.P.; Weiss, J.; Westerman, R.; Wijeratne, T.; Wyper, G.M.; Yano, Y.; Yimer, E.M.; Yonemoto, N.; Yousefifard, M.; Zaidi, Z.; Zare, Z.; Vos, T.; Feigin, V.L.; Murray, C.J. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* **2019**, *18*, 88–106. doi:10.1016/S1474-4422(18)30403-4.

- 62. Loy, C.T.; Schofield, P.R.; Turner, A.M.; Kwok, J.B.J. Genetics of dementia. *Lancet (London, England)* 2014, 383, 828–840. doi:10.1016/S0140-6736(13)60630-3.
- 63. Holtzman, D.M.; Herz, J.; Bu, G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harbor perspectives in medicine* **2012**, *2*, a006312. doi:10.1101/cshperspect.a006312.











¢

